Meeting
2017 ASCO Annual Meeting
Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).
Authors
Gabriel N. Hortobagyi
The University of Texas MD Anderson Cancer Center, Houston, TX
Gabriel N. Hortobagyi , Salomon M. Stemmer , Howard A. Burris III, Yoon Sim Yap , Gabe S. Sonke , Shani Paluch-Shimon , Mario Campone , Katarina Petrakova , Kimberly L. Blackwell , Eric P. Winer , Wolfgang Janni , Sunil Verma , Pier Franco Conte , Carlos L. Arteaga , David A. Cameron , Fengjuan Xuan , Michelle Kristine Miller , Caroline Germa , Samit Hirawat , Joyce O'Shaughnessy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT01958021
Citation
J Clin Oncol 35, 2017 (suppl; abstr 1038)
DOI
10.1200/JCO.2017.35.15_suppl.1038
Abstract #
1038
Poster Bd #
30
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
First-line (1L) ribociclib (RIB) plus letrozole (LET) for postmenopausal women with hormone receptor-positive (HR+), HER2- advanced breast cancer (ABC): MONALEESA-2 long-term safety results.
First Author: Joyce O'Shaughnessy
Poster
2017 ASCO Annual Meeting
First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.
First Author: Wolfgang Janni
Poster
2018 ASCO Annual Meeting
First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses.
First Author: Gabriel N. Hortobagyi
Poster
2023 ASCO Annual Meeting
CAPTOR-BC: Comprehensive analysis of spatial, temporal and molecular biomarkers predicting response and resistance to first-line treatment with ribociclib + ET in HR+, HER2- advanced breast cancer.
First Author: Peter A. Fasching